Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Sarrah Strimel Bentley and her boyfriend, James, were walking their dog at sunset when she felt an itch under her armpit. She ...

The Tobias-Lechleiter Institute for Clinical Innovation will serve as a hub for "groundbreaking" disease detection and ...

Drugmaker Eli Lilly and Company has hired Sandy Rodriguez as SVP and chief communications officer, effective on June 9. Rodriguez will report to Jennifer Oleksiw, SVP and global chief customer officer ...

Eli Lilly is turning up the volume on gene therapy with a $1.3 billion partnership with Rznomics to tackle sensorineural ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: LLY) has announced a series of executive leadership transitions aimed at bolstering the company’s growth trajectory, particularly in the U.S. and ...

Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:LLY) revealed 30 unusual trades. Delving into the details, we found 50% of ...

Eli Lilly's Q1 report showed strong earnings and sales growth. The company posted adjusted earnings per share (EPS) of $3.34 on $12.73 billion in sales. Wall Street had expected $3.02 on $12.67 ...

Eli Lilly said the revision reflects a $1.57 billion deal charge recorded in the first quarter, which is primarily related to its acquisition of a certain oral cancer drug from Scorpion Therapeutics.

Eli Lilly CEO Dave Ricks on Thursday said the drugmaker can help "respond" to national security concerns around cheaper essential medicines as pharmaceutical-specific tariffs loom. The Trump ...